246 related articles for article (PubMed ID: 29800007)
1. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
Donaldson M; Owen JL; Choi JN
JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
[No Abstract] [Full Text] [Related]
2. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
Arianayagam S; Ieremia E; Matin RN
Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
[No Abstract] [Full Text] [Related]
3. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
Hwang SJE; Fernández-Peñas P
Curr Probl Dermatol; 2018; 53():82-92. PubMed ID: 29131040
[TBL] [Abstract][Full Text] [Related]
4. Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings.
Cervantes J; Rosen A; Dehesa L; Dickinson G; Alonso-Llamazares J
Actas Dermosifiliogr (Engl Ed); 2019; 110(1):43-49. PubMed ID: 30389125
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab-associated halo-like inflammatory reactions around nevi during therapy for metastatic melanoma.
Alniemi DT; Fischer A; Greene LA; Pierson JC
Dermatol Online J; 2018 Jul; 24(7):. PubMed ID: 30261564
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study.
Dika E; Ravaioli GM; Fanti PA; Piraccini BM; Lambertini M; Chessa MA; Baraldi C; Ribero S; Andrea A; Melotti B; Patrizi A
Eur J Dermatol; 2017 Jun; 27(3):266-270. PubMed ID: 28524050
[TBL] [Abstract][Full Text] [Related]
7. [Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma].
Amini-Adle M; Balme B; Dalle S
Ann Dermatol Venereol; 2018 Dec; 145(12):802-803. PubMed ID: 30415933
[No Abstract] [Full Text] [Related]
8. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
Sato M; Uhara H; Koga H; Okuyama R
J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228
[No Abstract] [Full Text] [Related]
9. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
Hammami MB; Gill R; Thiruvengadam N; Oh DY; Beck K; Mahadevan U; Kattah MG
Dig Dis Sci; 2019 Mar; 64(3):685-688. PubMed ID: 30778872
[No Abstract] [Full Text] [Related]
10. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.
Adler NR; Murray WK; Brady B; McCormack C; Pan Y
Clin Exp Dermatol; 2018 Jun; 43(4):497-499. PubMed ID: 29396853
[No Abstract] [Full Text] [Related]
11. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.
Perret RE; Josselin N; Knol AC; Khammari A; Cassecuel J; Peuvrel L; Dreno B;
Int J Dermatol; 2017 May; 56(5):527-533. PubMed ID: 28188628
[TBL] [Abstract][Full Text] [Related]
12. Diet-dependent toxicity of ipilimumab in metastatic melanoma.
Majenka P; Hoffmann M; Rötzer I; Dimitrakopoulou-Strauss A; Koschny R; Longerich T; Enk A; Hassel JC
Eur J Cancer; 2019 Jan; 106():220-224. PubMed ID: 30528806
[No Abstract] [Full Text] [Related]
13. Novel therapies for unresectable and metastatic melanoma.
Karimkhani C; Reddy BY; Dellavalle RP; Sundararajan S
BMJ; 2017 Nov; 359():j5174. PubMed ID: 29191943
[No Abstract] [Full Text] [Related]
14. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.
Nardin C; Jeand'heur A; Bouiller K; Valnet-Rabier MB; Dresco F; Castagna J; Mareschal A; Carlet C; Nerich V; Limat S; Puzenat E; Aubin F
J Am Acad Dermatol; 2020 Mar; 82(3):770-772. PubMed ID: 31734192
[No Abstract] [Full Text] [Related]
15. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
[No Abstract] [Full Text] [Related]
16. Acute localised exanthematous pustulosis secondary to pembrolizumab.
Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
[No Abstract] [Full Text] [Related]
17. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
[No Abstract] [Full Text] [Related]
18. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
Tsiogka A; Jansky GL; Bauer JW; Koelblinger P
Melanoma Res; 2017 Oct; 27(5):524-525. PubMed ID: 28858175
[No Abstract] [Full Text] [Related]
19. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
[No Abstract] [Full Text] [Related]
20. [Treating metastatic melanoma: Risk management].
Lebbe C; Robert C
Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
[No Abstract] [Full Text] [Related]
[Next] [New Search]